Sionna Therapeutics Investigation

Robbins LLP is Investigating the Recent Stock Drop of Sionna Therapeutics

Robbins LLP is investigating Sionna Therapeutics (NASDAQ: SION) to determine whether certain Sionna Therapeutics officers and directors violated securities laws and breached fiduciary duties to shareholders.

Why Are We Investigating Sionna Therapeutics?

On Monday, August 10, 2026, Sionna Therapeutics stock plunged 92% to close at $4.51 after the Company reported disappointing results from its Phase 2a proof-of-concept study of SION-719 in cystic fibrosis.

According to media reports, the PreciSION CF trial failed to achieve its key activity endpoint, which measured the reduction in sweat chloride – a key marker of treatment success – when SION-719 was administered alongside the standard-of-care treatment Trikafta.

Though the Company finished the second quarter with “substantial financial resources,” it intends to take measures to preserve capital while determining the appropriate path forward for its clinical pipeline.


What Can Shareholders Do Now?

If you lost money investing in Sionna Therapeutics., submit a form for more information.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Send us a message for more information.

Additional Alerts for Shareholders

Yiren

Yiren Digital Ltd. Class Action Lawsuit

Robbins LLP is Investigating Allegations that Yiren Digital Ltd. (YRD) Misled Investors By Failing to Disclose Its Significant Exposure to the Financial Distress, Credit Risk, and Legal and Regulatory Problems of Its Controlling Shareholder, CreditEase, and Related Affiliates

Read More »
Free!
Skip to content